Roberto Visintainer results 1
· Newest (Page 1/1, per page 25)
Author: Roberto Visintainer ×Clear All Filters
Search Results
The fusion of therapeutic proteins to the Fc domain of monoclonal antibodies (mAbs) generally improves the proteins' pharmacokinetic (PK) characteristics, extending in vivo half-lives due to the binding of the Fc domain to the FcRn receptor. Yet, several of these Fc-fusion biologics have been observed to have unexpected rapid clearance associated with non-specific off-target binding. Variability in non-specific clearance is of...
Previous1Next